Due to early interruption of our study, however, we cannot make definite conclusion on the effects of SGLT2 inhibitors on peak VO2, while we hope that ongoing clinical trials, such as the EMPA‐TROPISM will provide a final answer, also in patients without T2DM.32 This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.